Pique Therapeutics is a biopharmaceutical company seeking to become the leader in the development of new therapeutic vaccines, focused initially on the treatment of cancer.

Pique's lead product is a first-in-class therapeutic vaccine (PT 107) for the treatment of non-small cell lung cancer. PT 107 is currently being studied in a randomized, double-blind Phase 2 clinical trial, which launched in the spring of 2011.

This pivotal Phase 2 trial is designed to enroll 100 patients with late-stage non-small cell lung cancer who have failed previous therapy, and is currently enrolling at over 10 clinical sites. The Phase 2 trial seeks to confirm the safety of PT 107, and further evaluate the efficacy of the drug, with overall survival as the primary endpoint.


In a Phase 1 clinical trial, PT 107 showed a dramatic improvement in median survival of 11 months, more than doubling the 4 to 6 months expected survival. One-third of the patients had a clinical response following treatment, and over 30% of the patients survived more than 4 years. The drug was well-tolerated, with a very good safety profile, with no drug-related serious adverse events.

Pique is also utilizing its novel therapeutic vaccine technology in additional areas of oncology, with products in pre-clinical stage for pancreatic, colorectal, and head and neck cancers.

The Company was founded on the research of Eckhard R. Podack, M.D., Ph.D., who is Chair of the Department of Immunology and Microbiology at the University of Miami.